Inhibikase Therapeutics (IKT) Non-Current Assets (2021 - 2026)
Inhibikase Therapeutics (IKT) reported Non-Current Assets of $1.24 million for Q2 2026, compared with $58,605 a year earlier and up 7.7% from the prior quarter.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Non-Current Assets (2021 - 2026) Analysis & Trends
At the end of FY2025, Inhibikase Therapeutics posted Non-Current Assets of $1.1 million, up 637.3% from FY2024.
- Non-Current Assets has a three-year compound annual growth rate of 24.7% (FY2022 to FY2025).
- By year, Non-Current Assets came in at $148,537 in FY2024 (-49.8%), $295,599 in FY2023 (-47.7%) and $565,175 in FY2022.
- The Q2 2026 figure ranks as the highest quarterly Non-Current Assets in data going back to Q1 2021.
- Year over year, Non-Current Assets gained in three of the last seven quarters, with growth averaging 253.3%.
- The high point for year-over-year Non-Current Assets in five years was Q1 2026 (growth of 891.5%); the low point was Q2 2025 (a decline of 73.8%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $1.16 million (Q1 2026), $1.1 million (Q4 2025) and $1.06 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 141.29 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 101.45 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 125.00 Mn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 94.68 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 87.87 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 60.68 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 35.42 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 159.77 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 14.88 Bn |
| 10 | Inhibikase Therapeutics | 357.87 Mn | -227.60 Mn | - | 1.24 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.24 Mn |
| Mar 31, 2026 | 1.16 Mn |
| Dec 31, 2025 | 1.10 Mn |
| Sep 30, 2025 | 1.06 Mn |
| Jun 30, 2025 | 58,605.00 |
| Mar 31, 2025 | 116,564.00 |
| Dec 31, 2024 | 148,537.00 |
| Sep 30, 2024 | 186,772.00 |
| Jun 30, 2024 | 223,997.00 |
| Mar 31, 2024 | 260,264.00 |
| Dec 31, 2023 | 295,599.00 |
| Sep 30, 2023 | 330,030.00 |
| Jun 30, 2023 | 363,615.00 |
| Mar 31, 2023 | 534,752.00 |
| Dec 31, 2022 | 565,175.00 |
| Sep 30, 2022 | 594,824.00 |
| Jun 30, 2022 | 43,089.00 |
| Mar 31, 2021 | 2,783.00 |
API Access
Inhibikase Therapeutics Non-Current Assets API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=non-current-assets&ticker=IKT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "non-current-assets", "ticker": "IKT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=non-current-assets&ticker=IKT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();